GSK plc (GSK) reported adjusted earnings of 72 cents per American depositary share (“ADS”) in fourth-quarter 2023, missing the Zacks Consensus Estimate of 76 cents. Adjusted earnings rose 12% year over year on a reported basis and 25% at a constant exchange rate (CER).Quarterly revenues increased 9% on a reported basis and 15% on a CER basis to $10.1 billion (£8.1 billion), beating the Zacks Consensus Estimate of $9.8 billion. The upside can be attributed to rising vaccine sales, which was partially offset ...

Anavex Life Sciences (AVXL) closed the last trading session at $6.29, gaining 4.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $39.67 indicates a 530.7% upside potential.The mean estimate comprises three short-term price targets with a standard deviation of $0.58. While the lowest estimate of $39 indicates a 520% increase from the current price level, the most optimistic analys ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Inhibikase Therapeutics, Inc. (IKT) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 16% over the last 60 days.Eldorado Gold Corporation (EGO) : This mining and mineral exploration company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.5% over the last 60 days.3MongoDB, Inc. (MDB) : This database platform company has seen the Zacks Consensus E ...

Investors might want to bet on Anavex Life Sciences (AVXL) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ye ...

NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) disorders, today announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX®3-71 first-in ...

Placebo-controlled Phase 2 trial cleared by the FDA – Trial to begin in Q2 2024 Trial to include Schizophrenia validated clinical outcomes PANSS and EEG/ERP biomarkers Trial to study positive, negative, and cognitive domains of Schizophrenia based on ANAVEX®3-71's ability to synergistically activate both SIGMAR1 and M1 muscarinic receptors NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing di ...

BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Anavex Life Sciences Corp. (NASDAQ:AVXL) for potential securities law violations. Investors who have lost money in their Anavex Life Sciences Corp. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/avxl. What is this all about? On January 2, Anavex announced results from its Phase 2/3 EXCELLENCE clinical trial for its candidate ANAVEX ...

One stock that might be an intriguing choice for investors right now is Anavex Life Sciences Corp. (AVXL) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably ta ...

Anavex Life Sciences Corp. (NASDAQ:AVXL) Q4 2023 Earnings Call Transcript November 27, 2023 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President and CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Trading Tom Bishop - Bishop Research Operator Good morning, and welcome to the Anavex Life Sciences Fiscal 2023 Fourth Quarter Conference Call. My name is Clint Tomlinson and I will be your host for today's call. At this time all pa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to________________ Commission file number: 001-37606 ANAVEX LIFE SCIENCES CORP. (Exact name of registrant as specified in its charter) Nevada 98-06084 ...